Live Stocks get clobbered as Trump's China trade war intensifies. See the latest. Dusseldorf - Delayed Quote • EUR Cerus Corp (CU2.DU) Follow Compare 1.1240 -0.1010 (-8.24%) At close: 7:31:29 PM GMT+2 All News Press Releases SEC Filings Cerus Leads Our Selection Of 3 Promising Penny Stocks As U.S. stocks attempt to recover from recent downturns, with the S&P 500 and Nasdaq aiming to end their losing streaks, investors are navigating a market filled with uncertainty yet ripe with potential opportunities. Penny stocks, though often overlooked in favor of more established names, remain an intriguing investment area for those seeking growth in smaller or newer companies. By focusing on firms with strong financial foundations and clear paths to growth, investors can uncover... Are Investors Undervaluing Cerus Corporation (NASDAQ:CERS) By 49%? Key Insights Using the 2 Stage Free Cash Flow to Equity, Cerus fair value estimate is US$2.99 Current share price of... Cerus secures CE mark approval for LED-based illumination device Cerus states that the CE mark represents the first regulatory approval for its “next generation” illuminator. Cerus Corporation Announces Receipt of CE Mark for Next-Generation INTERCEPT Illumination Device (INT200) CONCORD, Calif., March 05, 2025--Cerus Corporation (Nasdaq: CERS) announced today the CE mark approval of its next-generation LED-based illumination device, or the INT200, for the INTERCEPT Blood System for platelets and plasma under the European Union (EU) Medical Device Regulation (MDR). This approval allows Cerus to market the INT200 throughout the EU and in other regions that recognize the CE mark. Some countries may require additional in-country regulatory approval prior to commercializatio Cerus Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag Cerus ( NASDAQ:CERS ) Full Year 2024 Results Key Financial Results Revenue: US$180.3m (up 15% from FY 2023). Net loss... Cerus Corp (CERS) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Positive Cash Flow Cerus Corp (CERS) reports a 15% increase in annual product revenue and achieves positive adjusted EBITDA, despite challenges in foreign exchange and gross margins. Cerus: Q4 Earnings Snapshot CERS) on Thursday reported a loss of $2.5 million in its fourth quarter. On a per-share basis, the Concord, California-based company said it had a loss of 1 cent. The biomedical products company posted revenue of $50.8 million in the period. Cerus Corporation Announces Full-Year and Fourth Quarter 2024 Financial Results CONCORD, Calif., February 20, 2025--Cerus Corporation (Nasdaq: CERS) today announced financial results for its full year and fourth quarter ended December 31, 2024. Cerus Corporation to Participate in the TD Cowen 45th Annual Health Care Conference CONCORD, Calif., February 19, 2025--Cerus Corporation (Nasdaq: CERS) announced today that members of Cerus’ management are scheduled to present at the TD Cowen 45th Annual Health Care Conference on Wednesday, March 5, at 11:10 a.m. EST. US Penny Stocks To Watch In February 2025 As the S&P 500 hovers near record highs and treasury yields drop following retail sales data, investors are keeping a close eye on the broader U.S. market trends. Penny stocks, often associated with smaller or newer companies, remain an intriguing investment area despite their vintage name. These stocks can offer a blend of affordability and growth potential when backed by solid financials, making them worth considering for those seeking opportunities in this unique segment of the market. Cerus Corporation to Release Fourth Quarter and Full-Year 2024 Financial Results on February 20, 2025 CONCORD, Calif., February 07, 2025--Cerus Corporation (Nasdaq: CERS) announced today that its fourth quarter and full-year 2024 financial results will be released on Thursday, February 20, 2025, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management will discuss the Company’s financial results and provide a general business overview and outlook. Cerus Corporation Announces Preliminary Fourth Quarter and Full-Year 2024 Product Revenue and Provides Business Update CONCORD, Calif., January 13, 2025--Cerus Corporation (Nasdaq: CERS) today announced preliminary product revenue for the fourth quarter and full-year 2024 and provided product revenue guidance for full-year 2025. Cerus And 2 Other US Penny Stocks With Promising Potential The U.S. stock market has recently experienced a surge, with major indexes like the Dow Jones and Nasdaq showing significant gains, driven by strong performances in technology stocks and a notable rise in Bitcoin. Amidst this backdrop, penny stocks continue to capture investor interest as they offer unique opportunities for growth at lower price points. Though often associated with smaller or newer companies, these stocks can present substantial potential when backed by solid financials and... Cerus And 2 Other US Penny Stocks To Watch The U.S. stock market recently experienced a stumble, particularly in technology shares, as investors assessed earnings reports and economic data amidst fluctuating interest rates and inflation expectations. In such a climate, the appeal of penny stocks remains significant for those seeking affordable entry points with potential growth prospects. While the term "penny stocks" may seem outdated, these typically smaller or newer companies can offer unique opportunities when supported by strong... Cerus Corporation to Participate in Upcoming Investor Conferences CONCORD, Calif., November 13, 2024--Cerus Corporation (Nasdaq: CERS) announced management participation in two upcoming investor conferences. Cerus Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag Cerus ( NASDAQ:CERS ) Third Quarter 2024 Results Key Financial Results Revenue: US$46.0m (up 16% from 3Q 2023). Net... Q3 2024 Cerus Corp Earnings Call Q3 2024 Cerus Corp Earnings Call Cerus Corp (CERS) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ... Cerus Corp (CERS) reports a robust 16% increase in product revenue and raises full-year guidance, while navigating supply chain issues and regulatory hurdles. Cerus (CERS) Reports Q3 Loss, Tops Revenue Estimates Cerus (CERS) delivered earnings and revenue surprises of 33.33% and 4.35%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock? Discovering Opportunities: AlloVir And 2 Other US Penny Stocks As the U.S. stock market navigates a landscape shaped by mixed economic data and ongoing corporate earnings reports, investors are keenly observing potential opportunities across various sectors. Penny stocks, a term that may seem outdated, still capture the essence of investing in smaller or emerging companies with potential for growth. By focusing on those with strong financials and clear growth prospects, investors can uncover hidden gems amidst these lesser-known equities. Performance Overview Trailing total returns as of 4/10/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) Return CU2.DU S&P 500 (^GSPC) YTD -23.64% -10.43% 1-Year -28.41% +2.08% 3-Year -76.44% +17.37%